Patents by Inventor Serge St. Pierre

Serge St. Pierre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods involving long lasting synthetic exendin-4 peptide conjugates
    Patent number: 8093206
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: December 14, 2005
    Date of Patent: January 10, 2012
    Assignee: Conjuchem, LLC
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Methods involving long lasting synthetic exendin-4-peptide conjugates
    Patent number: 8084414
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: August 30, 2005
    Date of Patent: December 27, 2011
    Assignee: Conjuchem, LLC
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic exendin-4 peptide conjugates
    Patent number: 8080516
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: June 29, 2005
    Date of Patent: December 20, 2011
    Assignee: Conjuchem, LLC
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk LeBlanc, Serge St. Pierre
  • Protection of exendin-4 peptides through conjugation
    Publication number: 20090093408
    Abstract: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a react group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity.
    Type: Application
    Filed: August 1, 2008
    Publication date: April 9, 2009
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic exendin-4 peptide conjugates and methods of use thereof
    Publication number: 20090075890
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: August 1, 2008
    Publication date: March 19, 2009
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon like peptide (GLP-1)
    Publication number: 20060135426
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: December 14, 2005
    Publication date: June 22, 2006
    Applicant: CONJUCHEM, INC.
    Inventors: Dominique Bridon, Benoit L' Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon like peptide (GLP-1)
    Publication number: 20060058235
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: August 30, 2005
    Publication date: March 16, 2006
    Applicant: CONJUCHEM, INC.
    Inventors: Dominique Bridon, Benoit L'Archeveque, Alan Ezrin, Darren Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon-like peptide {GLP-1}
    Patent number: 6887849
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: May 3, 2005
    Assignee: ConjuChem, Inc.
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon-like peptide (GLP-1)
    Patent number: 6821949
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: November 23, 2004
    Assignee: ConjuChem, Inc.
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon like peptide (GLP-1)
    Publication number: 20040138100
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: November 25, 2003
    Publication date: July 15, 2004
    Applicant: CONJUCHEM, INC.
    Inventors: Dominique Bridon, Benoit L' Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon like peptide (GLP-1)
    Publication number: 20040127398
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: November 25, 2003
    Publication date: July 1, 2004
    Applicant: CONJUCHEM, INC.
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting insulinotropic peptides
    Patent number: 6593295
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: July 15, 2003
    Assignee: Conjuchem, Inc.
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon-like peptide {GLP-1}
    Publication number: 20030108567
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: November 4, 2002
    Publication date: June 12, 2003
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon-like peptide {GLP-1}
    Publication number: 20030108568
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: November 4, 2002
    Publication date: June 12, 2003
    Inventors: Dominique P. Bridon, Benoit L' Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting synthetic glucagon like peptide {GLP-!}
    Patent number: 6514500
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: February 4, 2003
    Assignee: Conjuchem, Inc.
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting insulinoptropic peptides
    Publication number: 20020049153
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Application
    Filed: June 6, 2001
    Publication date: April 25, 2002
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Long lasting insulinotropic peptides
    Patent number: 6329336
    Abstract: Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
    Type: Grant
    Filed: September 5, 2000
    Date of Patent: December 11, 2001
    Assignee: Conjuchem, Inc.
    Inventors: Dominique P. Bridon, Benoit L'Archeveque, Alan M. Ezrin, Darren L. Holmes, Anouk Leblanc, Serge St. Pierre
  • Artificial collagen
    Patent number: 5856308
    Abstract: The invention provides artificial collagen comprising a stabilized ordered triple helix of copolypeptide strands containing repeating amino acid triads. The collagen may be modified with groups which improve its physical or chemical properties for the intended use, such as adhesive and cross-linking groups. Artificial collagen according to the invention is particularly useful as a wound closer and healer.
    Type: Grant
    Filed: September 27, 1996
    Date of Patent: January 5, 1999
    Assignee: Haemacure Corporation
    Inventors: Serge St. Pierre, Teresa Brodniewicz